| 引用本文:田颖，樊健敏，杨冬艳.坤泰胶囊对围绝经期综合征患者生命质量与卵巢功能的影响评价[J].世界中医药,2019,(12):. |
|
| 坤泰胶囊对围绝经期综合征患者生命质量与卵巢功能的影响评价 |
| Effects Evaluation on Kuntai Capsule on Quality of Life and Ovarian Function in Patients with Perimenopausal Syndrome |
| 投稿时间：2019-03-22 |
| DOI：10.3969/j.issn.1673-7202.2019.12.033 |
| 中文关键词: 围绝经期综合征 坤泰胶囊 生命质量 卵巢功能 戊酸雌二醇，甲羟孕酮 |
| English Keywords:Perimenopausal syndrome Kuntai Capsule Quality of life Ovarian function Estradiol valerate Medroxyprogesterone |
| 基金项目:2016年陕西省科技计划项目（2016K11-01-01-07） |
|
| 摘要点击次数: 445 |
| 全文下载次数: 398 |
| 中文摘要: |
| 目的：观察坤泰胶囊对围绝经期综合征的影响，分析坤泰胶囊在围绝经期综合征中的治疗价值。方法：选取2016年6月至2018年6月陕西省中医医院收治的围绝经期患者146例作为研究对象，按照随机数字表法分为对照组和观察组，每组73例。对照组采用西医常规治疗，观察组采用坤泰胶囊辅助治疗，对比组间治疗前后的卵巢功能、生命质量变化的不同，同时比较组间临床疗效和药物不良反应的区别。结果：治疗前，观察组和对照组的FSH、AFC、LH、E2、MENQOL评分、临床症状评分比较，差异无统计学意义（P>0.05）；治疗后，观察组FSH(109.1±19.7)IU/L、AFC(4.2±0.9)个/单侧、LH(55.8±6.8)IU/L、E2(62.3±5.5)pg/mL，改善效果明显高于对照组，差异有统计学意义（P<0.05）；观察组临床症状评分(8.3±2.6)分、MENQOL评分(2.2±0.7)分明显低于对照组，差异有统计学意义（P<0.05）；观察组总有效率(89.04%)明显高于对照组，差异有统计学意义（P<0.05）；观察组药物不良反应发生率(6.8%)与对照组(9.6%)相近，差异无统计学意义（P>0.05）。结论：坤泰胶囊有利于减轻围绝经期综合征患者临床症状，改善患者卵巢功能、提高治疗效果、提升生命质量，是围绝经期综合征较为安全、可靠的辅助治疗药物。 |
| English Summary: |
| To observe the effects of Kuntai Capsule on perimenopause syndrome and analyze the therapeutic value of Kuntai Capsule in perimenopause syndrome.Methods:From June 2016 to June 2018, 146 perimenopause patients who were treated in Shaanxi Traditional Chinese Medicine Hospital were randomly divided into a control group(conventional western medicine treatment)and an observation group(Kuntai Capsule adjunct therapy), with 73 cases in each group.The changes of ovarian function and quality of life before and after treatment were observed.The clinical efficacy and drug side effects between groups were compared.Results:Before the treatment, there was no significant difference between the 2 groups in the FSH, AFC, LH, E2, MENQOL score and clinical symptom score of the observation group and the control group(P>0.05).After the treatment, the improvement effect of FSH(109.1±19.7)IU/L, AFC(4.2±0.9)/unilateral, LH(55.8±6.8)IU/L, E2(62.3±5.5)pg/mL in the observation group was significantly higher than those in the control group(P<0.05).The difference was statistically significant.The scores of clinical symptoms(8.3±2.6)and MENQOL(2.2±0.7)in the observation group were significantly lower than those in the control group(P<0.05).There was statistical significance.The total effective rate of the observation group(89.04%)was significantly higher than that of the control group(P<0.05), and the difference was statistically significant.The incidence of side effects in the observation group(6.8%)was similar to that in the control group(9.6%)(P>0.05), and there was no significant difference between the observation group and the control group.Conclusion:Kuntai Capsule is a safe and reliable adjuvant therapy for perimenopause syndrome, which is beneficial to relieve the clinical symptoms, improve the ovarian function, the therapeutic effect and the quality of life of the patients with perimenopause syndrome. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
